Simple Summary Metastatic prostate cancer is traditionally treated with androgen
deprivation therapy. The introduction of second-generation antiandrogens into clinical …

Introduction: Recently, an increasing number of systemic therapies with life extending
capacity have become available in metastatic castration resistant prostate cancer (mCRPC) …

Simple Summary Prostate cancer may in some cases exhibit microscopic and molecular
characteristics of a distinct subtype of disease which is referred to as neuroendocrine …

Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies
are based largely on anatomical and pathological parameters. In the recent past, several …

Introduction The extensive heterogeneity of prostate cancer (PCa) and multilayered
complexity of progression to castration-resistant prostate cancer (CRPC) have contributed to …

Background Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current
biomarkers is difficult and often results in unnecessary invasive procedures as well as over …

Abstract Purpose of Review This review will examine the taxonomy of PCa subclasses
across disease states, explore the relationship among specific alterations, and highlight …

5013 Background: The AVPC are a subset of prostate cancers that share the clinical,
therapy response and molecular profiles of the small cell prostate carcinomas, a histological …

Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has
led to a striking improvement of response rate and survival in both hormone-sensitive and …

5055 Background: AVPCa shares clinical features with small cell carcinoma (SCC) such as
resistance to androgen signaling inhibition and frequent visceral metastases. A prospective …